A monoclonal antibody Covid treatment from Vir Biotechnology and GlaxoSmithKline "stands up well" to all variants of the virus, Vir President and CEO George Scangos told CNBC's "Power Lunch" on Wednesday.Scangos' comments came after the two companies announced contracts to sell $1 billion worth of their antibody, sotrovimab, to the U.S. government. The Food and